ArticleActa obstetricia et gynecologica Scandinavica2026
Assessing quality standards of biomarker measurement in first-trimester combined screening for preeclampsia in the Chinese population: A multicenter study.
Article in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe first-trimester combined screening test for preterm preeclampsia (preterm-PE) has been implemented in Mainland China. This study aims, first, to evaluate the applicability of multiple of the median (MoM) models based on biomarkers developed and utilized in a European population for prospective preterm-PE screening in Mainland China; second, to assess the criteria for biomarker adjustment; and third, to establish criteria for continuous quality assurance in the screening process. MATERIAL AND
methodsIn this prospective multicenter cross-sectional study, 22 066 singleton pregnancies undergoing preterm-PE screening at 11
resultsAfter excluding the initial 400 pregnancies from each center, all PlGF, but not all MAP MoM distributions, required recentering. Post-recentering, the overall distribution median (95% confidence interval) MoM values for MAP and PlGF were 1.003 (1.001, 1.004) and 1.004 (0.996, 1.013), respectively.
conclusionsChinese centers performing combined PE screening should assess biomarker MoM distributions in their initial cases to ensure that they conform to the expected central tendencies assumed in the risk estimation models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.